All News

The benefits of taking aspirin to prevent a second or subsequent cardiovascular event have been well established in previous studies but the effectiveness of taking aspirin to prevent a first cardiovascular event has been unclear, despite 30 years of randomized clinical trials.

The data demonstrated that the lotion resulted in statistically significant reductions in both inflammatory and noninflammatory lesions compared to vehicle.

Officials with the FDA have approved the first monoclonal antibody, lanadelumab (Takhzyro, Shire) for the treatment of patients 12 years and older with types 1 and 2 hereditary angioedema (HAE), according to the agency.